SCHEMBL1774353

SCHEMBL1774353

CNC1CN(c2cc(NCc3cccc(F)c3)ncn2)C1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 5/20 0.70
PIK3CB P42338 1/20 0.48
CARM1 Q86X55 2/20 0.43
PRMT6 Q96LA8 2/20 0.43
KDM5A P29375 1/20 0.43
KDM4C Q9H3R0 1/20 0.43
KDM5B Q9UGL1 1/20 0.43
PRCP P42785 1/20 0.42
CCNT1 O60563 3/20 0.42
ADORA3 P0DMS8 3/20 0.40
ADORA2A P29274 3/20 0.40
ADORA1 P30542 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
AURKA O14965 1/20 0.40
DAPK3 O43293 1/20 0.40
JAK2 O60674 1/20 0.40
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
PAK4 O96013 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1774066 0.87 HRH4 (0.53) HRH4PIK3CBPRCPRAB9AJAK2
SCHEMBL1774199 0.87 HRH4 (0.66) HRH4PIK3CBPRCPCLK4
SCHEMBL12605054 0.83 HRH4 (1.00) HRH4PIK3CB
SCHEMBL1774310 0.81 HRH4 (0.48) HRH4PIK3CBKDM5AKDM4CKDM5B
SCHEMBL18601592 0.79 KDM5A (0.48) HRH4PIK3CBKDM5AKDM4CKDM5B
SCHEMBL12604971 0.77 HRH4 (0.44) HRH4PIK3CBKDM5AKDM4CKDM5B
SCHEMBL1774241 0.77 HRH4 (0.52) HRH4
SCHEMBL1774263 0.76 HRH4 (0.47) HRH4PIK3CBPRCPNPC1RAB9A
SCHEMBL1774043 0.74 HRH4 (0.50) HRH4
SCHEMBL1774192 0.73 HRH4 (0.54) HRH4PRCP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966162-B1 PYRIMIDINE DERIVATIVES ZIARCO PHARMA LTD (GB) 2017-03-15 EP disclosed
EP-1966162-B1 PYRIMIDINE DERIVATIVES ZIARCO PHARMA LTD (GB) 2017-03-15 EP disclosed
CN-101341134-B Pyrimidine derivatives PFIZER LTD 2013-05-01 CN disclosed
US-7943628-B2 Pyrimidine derivatives PFIZER LIMITED (GB) 2011-05-17 US disclosed
US-7943628-B2 Pyrimidine derivatives PFIZER LIMITED (GB) 2011-05-17 US disclosed
US-7943628-B2 Pyrimidine derivatives PFIZER LIMITED (GB) 2011-05-17 US disclosed
CN-101341134-A Pyrimidine derivatives PFIZER LTD (GB) 2009-01-07 CN disclosed
EP-1966162-A2 PYRIMIDINE DERIVATIVES Pfizer Limited (GB) 2008-09-10 EP disclosed
US-20070185075-A1 Pyrimidine derivatives PFIZER LIMITED 2007-08-09 US disclosed
US-20070185075-A1 Pyrimidine derivatives PFIZER LIMITED 2007-08-09 US disclosed
US-20070185075-A1 Pyrimidine derivatives PFIZER LIMITED 2007-08-09 US disclosed
WO-2007072163-A2 PYRIMIDINE DERIVATIVES PFIZER LIMITED (GB) 2007-06-28 WO disclosed
WO-2007072163-A2 PYRIMIDINE DERIVATIVES PFIZER LIMITED (GB) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185075-A1 Pyrimidine derivatives TYMS, DPYD, TYMP HRH4 184/4885PIK3CB 1970/4885CARM1 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.